FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	$D \subset$	20549	
vasilligion,	D.C.	20349	

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Troendle August J.</u>						2. Issuer Name and Ticker or Trading Symbol Medpace Holdings, Inc. [MEDP]										o of Reporti licable) tor		rson(s) to			
(Last) (First) (Middle) C/O MEDPACE HOLDINGS, INC. 5375 MEDPACE WAY					07/	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2021									X Officer (give title Other (specify below) President & CEO						
(Street)					4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)										Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)		(Stat	, ,	ip)																	
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/You				2A. Deemed Execution Date,		<u>, </u>	3. Transaction Code (Instr.		4. Securities Disposed Of	5. Amo		unt of ies	6. Ownership Form: Direct		7. Nature of Indirect						
					(Month/Day/Year) if any (Month/Day/Year)		ar)	Code (v	Amount	(A) or (D)	or Price		Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		(D) or Indirect (I) (Instr. 4)		Beneficial Ownership (Instr. 4)	
Common Stock				07/01/2021					S ⁽¹⁾		238(1)	D	\$180	\$180.03 ⁽²⁾		6,229,135		I	By Medpace Investors, LLC ⁽³⁾		
Common Stock				07/02/2021					S ⁽¹⁾		3,556(1)	D	\$180	.16(4)	6,225,579		I		By Medpace Investors, LLC ⁽³⁾		
Common Stock														70	6,643		D				
			Tak	ole I	I - Derivati (e.g., pu							sposed of, , convertil				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversi or Exerci Price of Derivativ Security	nversion Date Exercise (Month/Day/Year) 3. Transaction Date Exercise ce of rivative curity 3. Transaction Exercise (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Nu of Deriv Code (Instr. 8) 5. Nu of Code (Instr. 8) 6. Nu of Deriv Code (Instr. 8) 7. Nu of Deriv Code (Instr. 8) 7. Nu of Code (mber ative rities ired osed	6. Da Expi (Moi	ate Ex	ercisable and	7. Titl Amou Secur Unde Deriv	e and unt of rities rlying ative rity (Insi 4)	8. F Der See (Ins	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)			
						Code	v	(A) (D)		Date Exercisab		Expiration Date	Title	Numb of Share							

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Medpace Investors, LLC ("MPI") on March 12, 2021.
- 2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$180.00 to \$180.20. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
- 3. The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- 4. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from \$180.00 to \$180.50. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

/s/ Stephen P. Ewald, Attorney-in-Fact for August J. 07/06/2021 **Troendle**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.